Affimed NV (NASDAQ:AFMD) Receives $4.99 Consensus Price Target from Brokerages

Share on StockTwits

Affimed NV (NASDAQ:AFMD) has received a consensus rating of “Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $4.99.

Several brokerages have recently commented on AFMD. ValuEngine raised Affimed from a “hold” rating to a “buy” rating in a research note on Wednesday, March 20th. Zacks Investment Research raised Affimed from a “hold” rating to a “strong-buy” rating and set a $4.75 price objective for the company in a research note on Friday, March 29th. Svb Leerink began coverage on Affimed in a research note on Thursday, March 28th. They issued an “outperform” rating and a $8.00 price objective for the company. Finally, Leerink Swann began coverage on Affimed in a research note on Thursday, March 28th. They issued an “outperform” rating and a $4.17 price objective for the company.

Shares of Affimed stock traded up $0.02 on Friday, hitting $2.62. The company had a trading volume of 610,279 shares, compared to its average volume of 721,829. The company has a market cap of $163.46 million, a PE ratio of -6.89 and a beta of 3.09. Affimed has a 1 year low of $1.40 and a 1 year high of $7.35. The company has a quick ratio of 3.16, a current ratio of 3.17 and a debt-to-equity ratio of 0.03.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings data on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.19. The firm had revenue of $12.89 million during the quarter, compared to the consensus estimate of $6.77 million. Affimed had a negative return on equity of 23.61% and a negative net margin of 29.04%. As a group, research analysts anticipate that Affimed will post -0.28 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Stonepine Capital Management LLC purchased a new stake in shares of Affimed during the fourth quarter valued at approximately $2,221,000. Lindbrook Capital LLC purchased a new stake in shares of Affimed during the fourth quarter valued at approximately $38,000. Sigma Planning Corp purchased a new stake in shares of Affimed during the first quarter valued at approximately $46,000. Prescott Group Capital Management L.L.C. increased its position in shares of Affimed by 16.1% during the fourth quarter. Prescott Group Capital Management L.L.C. now owns 190,680 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 26,480 shares during the last quarter. Finally, FDx Advisors Inc. purchased a new stake in shares of Affimed during the fourth quarter valued at approximately $87,000. 37.50% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Article: Different Options Trading Strategies

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Scotts Miracle-Gro Co  Holdings Increased by Sit Investment Associates Inc.
Scotts Miracle-Gro Co Holdings Increased by Sit Investment Associates Inc.
NumerixS Investment Technologies Inc Invests $120,000 in BorgWarner Inc.  Stock
NumerixS Investment Technologies Inc Invests $120,000 in BorgWarner Inc. Stock
NumerixS Investment Technologies Inc Has $110,000 Stake in II-VI, Inc.
NumerixS Investment Technologies Inc Has $110,000 Stake in II-VI, Inc.
VisionPoint Advisory Group LLC Acquires Shares of 3,925 iShares Core S&P Small-Cap ETF
VisionPoint Advisory Group LLC Acquires Shares of 3,925 iShares Core S&P Small-Cap ETF
NumerixS Investment Technologies Inc Buys New Holdings in Camden Property Trust
NumerixS Investment Technologies Inc Buys New Holdings in Camden Property Trust
Sawtooth Solutions LLC Has $393,000 Stake in Thermo Fisher Scientific Inc.
Sawtooth Solutions LLC Has $393,000 Stake in Thermo Fisher Scientific Inc.


© 2006-2019 Ticker Report